Equillium, Inc. is a clinical-stage biotechnology company developing novel therapeutics for severe autoimmune and inflammatory disorders. The company's pipeline focuses on immunomodulatory assets targeting immuno-inflammatory pathways, with primary indications in gastroenterology, dermatology, and pulmonology. Key product candidates include EQ504, a preclinical-stage aryl hydrocarbon receptor (AhR) modulator intended for ulcerative colitis and other gastrointestinal diseases, and EQ302, a first-in-class, selective bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery to treat celiac disease and inflammatory bowel disease. Equillium acquired exclusive worldwide rights to EQ504 through the acquisition of Ariagen, Inc. in October 2024, and obtained EQ302 via the acquisition of Bioniz Therapeutics, Inc. in February 2022. The company plans to advance these candidates through clinical development, with EQ504 scheduled for a Phase 1 proof-of-mechanism study in mid-2026. Its strategy includes expanding its pipeline through internal research and potential acquisitions of complementary therapeutic programs.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Biotechnology Homepage equilliumbio.com
Sector Healthcare IR page equilliumbio.com/investors
Tags
autoimmune diseases, inflammatory bowel disease, ulcerative colitis, celiac disease, gastroenterology, immunomodulation, aryl hydrocarbon receptor modulators, cytokine inhibitors, oral therapeutics, preclinical development, EQ504, EQ302, Ariagen Inc., Bioniz Therapeutics Inc.
Press page —

Metrics

Valuation  
Market cap $ 103.038M
Market cap (USD) $ 103.038M
P/E -23.21
PEG —
P/BV 1.96
P/S 2.51
P/OCF -6.71
P/FCF -6.65
Dividend yield —
Turnover / mcap —
Returns  
ROE -94.0%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 3
Quality score -41.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue — 41.095M 36.084M 15.759M — — — —
Net profit -22.398M -8.067M -13.335M -62.428M -39.052M -29.813M -25.6M -13.25M
Free cash flow -22.794M -19.111M -21.833M -9.012M -32.138M -24.826M -23.023M -7.561M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 1.55 0.75 0.72 1.09 3.77 5.35 3.38 8.16
Price performance 12m 1.07 0.03 -0.34 -0.71 -0.3 0.58 -0.59 —

Filed figures

Figure Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — — — — 0.00 2.84M 3.74M 0.00 —
↳ YoY growth +31.6% -100.0%
Borrowings, current (USD) — — — 1.67M 1.43M 5.71M — — —
Borrowings, non-current (USD) — — 9.68M 8.28M 8.75M 3.24M — — —
Lease liabilities (USD) — — — — 1.61M 1.23M 824,000 384,000 719,000
Cash and deposits (USD) 7.1M 28.5M 13.2M 24M 50.4M 59.1M 23.2M 18.1M 30.3M
Right-of-use assets (USD) — — — — 1.65M 1.19M 796,000 364,000 658,000
Net debt (borrowings + leases - cash) (USD) — — -3.54M -14M -38.6M -48.9M — — —
Cash flow detail
Operating cash flow (USD) — -7.53M -22.9M -24.6M -32.1M -8.73M -21.8M -19M -22.7M
Purchases of property, plant and equipment (USD) — -34,858 -74,000 -202,000 -57,000 -279,000 -50,000 -85,000 -48,000
Change in receivables (cash effect) (USD) — — — — — -2.84M -897,000 3.74M —
Change in payables (cash effect) (USD) — 842,722 775,000 894,000 -1.58M 2.51M 723,000 -2M -1.94M
Share buybacks (cash effect) (USD) — — — — — — -260,000 — —
Interest paid (cash effect) (USD) — — -142,000 -839,000 -836,000 -847,000 -946,000 — —
Income taxes paid (cash effect) (USD) — — — — — — -580,000 — -352,000
Share-based compensation (USD) — 441,914 2.25M 3.82M 4.41M 4.84M 4M 3.75M 2.32M
Operating cash flow before change in receivables (USD) — — — — — -5.9M -20.9M -22.8M —
Free cash flow (OCF - PPE - intangibles) (USD) — -7.56M -23M -24.8M -32.1M -9.01M -21.8M -19.1M -22.8M
Income detail
Research and development expense (USD) — 4.94M 17.6M 19.4M 26.4M 37.5M 37M 37.4M 12.8M
↳ 5y CAGR +49.6% +16.2% -7.9%
Total comprehensive income (USD) — -13.2M -25.6M -30.1M -38.9M -62.2M -13.3M -7.43M -22.8M
Comprehensive income to owners (USD) — -13.2M -25.6M -30.1M -38.9M -62.2M -13.3M -7.43M -22.8M
Reported Nov 15, 2018 Mar 27, 2019 Mar 26, 2020 Mar 24, 2021 Mar 23, 2023 Mar 23, 2023 Mar 25, 2024 Mar 27, 2025 Mar 25, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

First participant dosed in Phase 1 clinical trial of EQ504, proof-of-mechanism data expected in Q2 2027

Cash equivalents of $53.3 million as of September 30, 2026; pro forma cash balance of approximately $72.0 million after the net effect of $20 million in gross financing received in October 2026

Cash runway expected into 2029

LA JOLLA, California, November 12, 2026 – Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology innovator developing novel therapies to treat serious autoimmune and inflammatory disorders, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update highlighting recent progress with EQ504, its novel small-molecule aryl hydrocarbon receptor (AhR) modulator.

“We continue to make important progress advancing EQ504, with the recent initiation of clinical development marking a significant milestone for the program,” said Bruce Steel, Chief Executive Officer of Equillium. “We believe EQ504’s differentiated immunoregulatory mechanism of action, without broad immune suppression, has the potential to address key epithelial and immune pathways involved in inflammatory disease.

October 26, 2026

Download(opens in new window)

Topline Phase 1 proof-of-mechanism data anticipated in Q2 2027

Randomized, double-blind, placebo-controlled study will evaluate safety, tolerability, PK and PD of EQ504

Triggers Milestone Closing of $20 million in additional funding under previously announced equity private placement agreement; cash expected to fund currently planned operations into 2029

LA JOLLA, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that the first subject has been dosed in Australia in its Phase 1 clinical trial of EQ504, an investigational oral, colon-targeted aryl hydrocarbon receptor (AhR) modulator being developed for the treatment of serious inflammatory diseases (the Milestone Event). In connection with the occurrence of the Milestone Event, the Company also announced the anticipated milestone closing under its August 2025 equity private placement of an additional $20 million of shares of its common stock, or pre-funded warrants in lieu thereof (the Milestone Closing), which is expected to occur later today.

“Dosing the first participant in our Phase 1 trial marks an important milestone as we advance EQ504, our differentiated, oral, colon-targeted AhR modulator, into clinical development,” said Bruce Steel, Chief Executive Officer of Equillium. “We believe EQ504's locally acting and non-immunosuppressive approach has the potential to address important unmet medical needs in ulcerative colitis and other serious inflammatory diseases. The Phase 1 trial is designed to evaluate safety and tolerability, as well as characterize EQ504’s pharmacokinetic and pharmacodynamic profile to assess proof of mechanism. Subject to supportive topline Phase 1 data, expected in Q2 2027, we anticipate initiating a placebo-controlled proof-of-concept study in patients with moderately to severely active ulcerative colitis in the second half of 2027.”

The Phase 1 trial (NCT07869225 ), being conducted in Australia, is a randomized, double-blind, placebo-controlled, single-center study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of EQ504 in approximately 70 healthy subjects exploring once-daily oral doses ranging from 0.1–3.0 mg. The study consists of a single ascending dose portion evaluating escalating oral doses of EQ504 across five sequential cohorts, and a multiple ascending dose (MAD) portion evaluating once-daily oral dosing over 10 days across three cohorts.

The MAD portion will also evaluate EQ504's pharmacodynamic activity through multiple gastrointestinal (GI) mucosal biopsies, including measurement of cytochrome P450 1A1 (CYP1A1) expression, a biomarker of AhR pathway activation. These assessments are designed to provide early clinical evidence of localized target engagement and biological activity in the GI tract, supporting EQ504's differentiated, colon-targeted approach. An optional food-effect cohort will examine whether food affects EQ504 exposure.

Milestone Closing of $20 Million Under the August 2025 Equity Private Placement

At the Milestone Closing, investors are expected to purchase and the Company expects to issue and sell 14,957,260 shares of common stock at a purchase price of $0.57 per share and 20,130,457 pre-funded warrants to purchase common stock at a purchase price of $0.5669 per pre-funded warrant, for aggregate gross proceeds of approximately $20.0 million, bringing the total equity private placement proceeds to approximately $50 million. With the proceeds from the Milestone Closing, the Company expects its cash and cash equivalents to be sufficient to fund its currently planned operations into 2029.

The offer and sale of the foregoing securities were made in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or any applicable state securities laws. Accordingly, the securities may not be reoffered or resold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The investors have been granted customary resale Form S-3 registration rights for the shares of common stock issued to them in the financing.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About EQ504
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. For ulcerative colitis, EQ504 is formulated as an oral, colon-targeted delayed-release drug product. Equillium is also evaluating the potential of EQ504 for additional indications, including inflammatory lung diseases through inhaled formulations.

About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.

October 6, 2026

Download(opens in new window)

New preclinical data further characterizes EQ504’s coordinated effects across epithelial and immune compartments in intestinal inflammation

LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Equillium , Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that new preclinical data from its EQ504 program will be presented in a poster at the 50 th Anniversary La Jolla Immunology Conference , taking place October 6-8, 2026 in La Jolla, California.

“These data provide additional insight into the multi-modal activity of EQ504, demonstrating coordinated effects across epithelial and immune compartments that preserve barrier integrity while resolving inflammation,” said Dr. Stephen Connelly, Chief Scientific Officer of Equillium. “We believe these complementary effects are particularly relevant to ulcerative colitis, where both reducing inflammation and improving mucosal healing are important to achieving meaningful outcomes for patients.”

Details of the poster presentations:

Title: AhR activation stabilizes inflammatory crosstalk and promotes barrier repair in an intestinal co-culture model
Poster Number: I-37
Lead Author: Rosa Quinn Closser
Presentation Type: Poster Session 1
Date: October 6, 2026
Time: 11:00am to 1:00pm PT
Presentation Summary: EQ504 demonstrated coordinated effects across epithelial and immune compartments in an intestinal co-culture model, preserving barrier integrity while suppressing inflammatory cytokine production. These findings further support the potential of EQ504 to address both barrier dysfunction and inflammation in ulcerative colitis.

Following the presentation, the poster will be available on the Presentations page located under the Technology section of equilliumbio.com .

About EQ504
EQ504 is an investigational potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed to be complementary to other inflammation and immunology agents. AhR is critical to barrier organ tissue physiology and immunology, maintaining barrier function and promoting tissue repair and regeneration, while regulating resident immune cells with anti-inflammatory responses. EQ504’s preclinical properties provide the potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.

About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat severe autoimmune and inflammatory disorders.

Prompts

Equillium, Inc. (ticker EQ), listed in United States.

ETFs Holding Equillium, Inc.

ETF Weight in ETF Shares Market value As of
AVSC 0.00% 75,411 $ 86.723K Nov 16, 2026